Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

Leukemia. 2014 Nov;28(11):2267-70. doi: 10.1038/leu.2014.220. Epub 2014 Jul 16.

Authors

G Barosi¹, M-J Zhang², R Peter Gale³

Affiliations

¹ Center for the Study of Myelofibrosis, IRCCS Policlinico S, Matteo Foundation, Pavia, Italy.
² Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.
³ Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.

PMID: 25027516
DOI: 10.1038/leu.2014.220

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Follow-Up Studies
Humans
Janus Kinases / antagonists & inhibitors*
Myeloproliferative Disorders / drug therapy*
Myeloproliferative Disorders / mortality*
Nitriles
Pyrazoles / administration & dosage*
Pyrazoles / adverse effects*
Pyrimidines
Randomized Controlled Trials as Topic
Survival Rate

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib
Janus Kinases